# Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

> **NCT00410956** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 22 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** dexamethasone
- **DRUG:** floxuridine
- **GENETIC:** protein expression analysis
- **OTHER:** flow cytometry
- **OTHER:** immunoenzyme technique
- **OTHER:** immunohistochemistry staining method
- **OTHER:** immunologic technique
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** dynamic contrast-enhanced magnetic resonance imaging

## Key facts

- **NCT ID:** NCT00410956
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05-09
- **Primary completion:** 2024-05-07
- **Final completion:** 2024-05-07
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00410956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00410956, "Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00410956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*